Special considerations in low-tension glaucoma.
Low-pressure (low-tension) glaucoma is reviewed in relation to neuroprotection, that is, the therapeutic strategy to keep neurons living and functionally connected to targets within the brain. Baseline results of the Low-Pressure Glaucoma Treatment Study (LoGTS) are reviewed.
Krupin
Theodore
T
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. krupin@northwestern.edu
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D004311:Double-Blind Method; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000188:drug therapy*; D011810:Quinoxalines / Q000627:therapeutic use; D012165:Retinal Ganglion Cells / Q000187:drug effects*; D013999:Timolol / Q000627:therapeutic use; D014786:Vision Disorders / Q000188:drug therapy; D058609:Visual Field Tests; D014794:Visual Fields / Q000187:drug effects
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D018696:Neuroprotective Agents; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D013999:Timolol